1. Home
  2. MOVE vs NMRA Comparison

MOVE vs NMRA Comparison

Compare MOVE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Movano Inc.

MOVE

Movano Inc.

N/A

Current Price

$10.83

Market Cap

297.4M

Sector

Health Care

ML Signal

N/A

Logo Neumora Therapeutics Inc.

NMRA

Neumora Therapeutics Inc.

N/A

Current Price

$0.77

Market Cap

302.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MOVE
NMRA
Founded
2018
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.4M
302.0M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
MOVE
NMRA
Price
$10.83
$0.77
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$7.50
AVG Volume (30 Days)
299.3K
739.6K
Earning Date
04-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.23
EPS
N/A
N/A
Revenue
$433,000.00
N/A
Revenue This Year
$1,460.71
N/A
Revenue Next Year
$96.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$0.83
52 Week High
$34.87
$3.65

Technical Indicators

Market Signals
Indicator
MOVE
NMRA
Relative Strength Index (RSI) 42.90 19.21
Support Level $7.52 $0.83
Resistance Level $12.08 $1.74
Average True Range (ATR) 1.74 0.10
MACD -0.04 -0.05
Stochastic Oscillator 22.17 0.17

Price Performance

Historical Comparison
MOVE
NMRA

About MOVE Movano Inc.

Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: